T-Cell Factory

Kite Pharma acquires T-Cell Factory for $21M

Wednesday, March 18, 2015

Kite Pharma, a Santa Monica, Calif.-based, clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT) products based on CAR and TCR gene therapy platforms for the treatment of cancer, acquired T-Cell Factory (TCF), a privately held Dutch company, which has been renamed Kite Pharma E.U.

[Read More]